Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8507009 | 0.87 | IRAK4 (0.47) | HTTIRAK4ALDH1A1TSHRKDM4E | |
| SCHEMBL3377091 | 0.87 | IRAK4 (0.47) | HTTIRAK4ALDH1A1TSHRKDM4E | |
| SCHEMBL17374631 | 0.87 | IRAK4 (0.47) | HTTIRAK4ALDH1A1TSHRKDM4E | |
| SCHEMBL8508451 | 0.87 | IRAK4 (0.47) | HTTIRAK4ALDH1A1TSHRKDM4E | |
| SCHEMBL2257068 | 0.84 | GABRA1 (0.52) | HTTGABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL27577617 | 0.84 | GABRA1 (0.48) | HTTIRAK4GABRA1GABRB2ALDH1A1 | |
| SCHEMBL19143527 | 0.84 | KDM4E (0.49) | HTTIRAK4ALDH1A1TSHRKDM4E | |
| SCHEMBL27700923 | 0.84 | IRAK4 (0.45) | HTTIRAK4ALDH1A1TSHRKDM4E | |
| SCHEMBL725761 | 0.82 | GABRA1 (0.50) | IRAK4GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL28845213 | 0.82 | KDM4E (0.47) | HTTIRAK4ALDH1A1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473429-B | ROR gamma modulators | 领先制药控股公司 | 2021-09-10 | — | — | CN | claimed |
| EP-3724325-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | Codexis, Inc. (US) | 2020-10-21 | — | — | EP | claimed |
| WO-2019118557-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | CODEXIS, INC. (US) | 2019-06-20 | — | — | WO | claimed |
| WO-2013007663-A1 | 2-BENZYLSULFANYL[1,3,4]-OXADIAZOLE DERIVATIVES, AND MEDICAL USE THEREOF | Technische Universität Darmstadt (DE) | 2013-01-17 | — | — | WO | claimed |
| EP-2032141-A1 | INHIBITORS OF JANUS KINASES | Merck & Co., Inc. (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2008107677-A2 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SENEXIS LIMITED (GB) | 2008-09-12 | — | — | WO | claimed |
| WO-2007145957-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2007-12-21 | — | — | WO | claimed |
| EP-1370260-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-12-17 | — | — | EP | claimed |
| WO-2002066035-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-29 | — | — | WO | claimed |
| US-12286653-B2 | Carboxyesterase polypeptides for amide coupling | CODEXIS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| WO-2024105159-A1 | LIGANDS OF THE M6A-RNA READERS | UNIVERSITY OF ZURICH (CH) | 2024-05-23 | — | — | WO | disclosed |
| CN-117865997-A | Mixed hafnium amide complex and preparation method and application thereof | 江苏爱姆欧光电材料有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | ELAN PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
| EP-1497261-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004024081-A2 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| CN-1463974-A | Process for producing triazolopyrimidine derivative | XINGNONG CO LTD (CN) | 2003-12-31 | — | — | CN | disclosed |
| WO-2003091204-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | HTT 4591/4885IRAK4 1996/4885GABRA1 1882/4885 |
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | BACE1, PSEN1, BACE2 | HTT 330/4885IRAK4 2471/4885GABRA1 465/4885 |
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR1, FGFR3, FGFR4 | HTT 2868/4885IRAK4 1076/4885GABRA1 1315/4885 |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | HTT 81/4885IRAK4 2228/4885GABRA1 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.